Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEVANAC vs ALAWAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
Treatment of pain and inflammation associated with cataract surgery,Reduction of risk of macular edema following cataract surgery
Treatment of ocular itching associated with allergic conjunctivitis
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (Cr Cl <30 m L/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
Nepafenac is metabolized via ocular tissues to amfenac, the active metabolite. Systemic metabolism primarily involves hepatic conjugation and oxidation.
Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption.
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Nepafenac is approximately 98% bound to plasma proteins, primarily albumin.
Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd/F) is approximately 0.6 L/kg (range 0.5-0.7 L/kg), suggesting distribution into total body water and some tissue binding.
Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa.
Ophthalmic: Systemic bioavailability after topical ocular administration is very low (approximately 0.1-1% of the dose), but sufficient for local ocular effects. Oral bioavailability is not clinically relevant as drug is only used ophthalmically.
Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%.
No dose adjustment required in renal impairment; systemic exposure is minimal due to topical administration.
No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin.
No dose adjustment required in hepatic impairment; systemic exposure is minimal.
No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established.
Safety and efficacy in pediatric patients have not been established; use is not recommended.
Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established.
No specific dose adjustment; dosing is identical to standard adult dosing.
No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal.
No FDA black box warning.
None
Increased bleeding time due to antiplatelet effect,Delayed healing or corneal adverse events including keratitis and corneal perforation,Cross-sensitivity with aspirin or other NSAIDs,Use with caution in patients with bleeding diatheses or concurrent anticoagulants
For topical ophthalmic use only,Do not inject,Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting,May cause temporary blurred vision,Avoid touching dropper tip to any surface to prevent contamination
Hypersensitivity to nepafenac or any component of the formulation,History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs
Hypersensitivity to cetirizine or any component of the formulation
No clinically significant food interactions have been identified with ophthalmic nevanac. Systemic absorption is minimal, so dietary restrictions are not required.
No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application.
Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: generally considered lower risk for teratogenicity, but avoid if possible. Third trimester: increased risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Ophthalmic use results in minimal systemic absorption, but theoretical risks remain. Use only if clearly needed.
ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence.
No data on nepafenac in breast milk. Ophthalmic administration yields negligible systemic concentrations. M/P ratio not determined. Considered likely compatible with breastfeeding due to minimal absorption, but caution advised.
Azelastine is excreted in human breast milk; the milk-to-plasma ratio (M/P) is unknown. In a study of intranasal azelastine (2 sprays per nostril twice daily), the estimated daily infant dose via breast milk is 0.7% of the maternal dose, which is considered low. However, due to the potential for adverse effects in nursing infants (e.g., somnolence, irritability), caution is advised. Use only if clearly needed and benefit outweighs risk. Consider alternative therapies with more safety data.
No dose adjustments are typically required due to ophthalmic administration; systemic exposure is negligible. However, avoid use in third trimester unless potential benefit outweighs risk. No pharmacokinetic changes in pregnancy necessitate dose adjustment for topical ophthalmic formulation.
No specific dose adjustments are recommended for pregnancy. However, pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may reduce azelastine systemic exposure; the clinical significance is unknown. Use the lowest effective dose for the shortest duration. Maximum recommended intranasal dose: 2 sprays per nostril twice daily (total 548 mcg/day). Avoid exceeding this dose.
Nevanac (nepafenac) is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic suspension indicated for pain and inflammation associated with cataract surgery. Its prodrug formulation enhances corneal penetration, with active metabolite amfenac inhibiting COX-1 and COX-2. Administer one drop three times daily starting 1 day prior to surgery, continuing on day of surgery and for 2 weeks postoperatively. Avoid concurrent use of other NSAIDs or corticosteroids to mitigate risk of corneal adverse events. Monitor for signs of corneal epithelial breakdown, especially in patients with compromised corneal innervation (e.g., diabetes, prior ocular surgery).
Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting.
Wash hands before and after instilling the drop.,Remove contact lenses before use and wait 10 minutes after administering before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Apply one drop to the affected eye three times daily as directed, starting one day before cataract surgery.,Temporary blurred vision may occur; avoid driving or operating machinery until vision clears.,Notify your doctor if you experience eye pain, redness, sensitivity to light, or changes in vision.,Do not use other eye drops without consulting your doctor, especially other anti-inflammatory medications.,Store the bottle upright at room temperature, away from heat and light, and discard any unused suspension after the treatment period.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting.,Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses.,Do not use while wearing contact lenses if eyes are red or irritated.,Temporary burning or stinging may occur upon instillation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEVANAC vs ALAWAY, answered by our medical review team.
NEVANAC is a NSAID Ophthalmic that works by Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.. ALAWAY is a Ophthalmic Antihistamine that works by ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEVANAC and ALAWAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEVANAC is: One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.. The standard adult dose of ALAWAY is: 2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEVANAC and ALAWAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEVANAC is classified as Category C. Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: . ALAWAY is classified as Category C. ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.